| Title | Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarketsâ„¢. |
|---|
| URL | https://www.globenewswire.com/news-release/2025/02/26/3032524/0/en/Liquid-Biopsy-Market-Worth-US-11-3-billion-at-a-robust-CAGR-of-11-9-MarketsandMarkets.ht |
|---|
| Category | Fitness Health --> Health Articles |
|---|
| Meta Keywords | Liquid Biopsy Market |
|---|
| Meta Description | Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (CTC, ctDNA, cfDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-cancer (NIPT, Infectious)) Region - Global Forecast to 2029 |
|---|
| Owner | Healthcare101 |
|---|
| Description |
|---|
| The global Liquid Biopsy Market, valued at US$5.9 billion in 2023, is forecasted to grow at a robust CAGR of 11.9%, reaching US$6.4 billion in 2024 and an impressive US$11.3 billion by 2029. In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and monitoring. |
